CIDP (often misspelled as “CIPD”) stands for chronic inflammatory demyelinating polyneuropathy. It’s an autoimmune condition where your immune system attacks the protective coating around the nerves outside your brain and spinal cord, causing progressive weakness and numbness that worsens over at least eight weeks. It affects roughly 7 out of every 100,000 people and, while rare, is one of the most treatable chronic nerve disorders.
What Happens Inside Your Nerves
Your peripheral nerves, the ones running through your arms, legs, hands, and feet, are wrapped in a fatty insulating layer called myelin. Myelin works like the rubber coating on an electrical wire: it keeps signals moving fast and efficiently. In CIDP, your immune system mistakes this myelin for a threat. Immune cells infiltrate the nerve and physically strip away segments of the coating, slowing or blocking the electrical signals that control movement and sensation.
The damage is patchy rather than uniform. It tends to cluster near specific junction points along the nerve fiber called nodes of Ranvier, which are critical relay stations for signal transmission. About 10% of people with CIDP have identifiable antibodies that target proteins at these nodes. In everyone else, the attack appears to be driven by a broader immune response involving both antibodies and immune cells like macrophages, which wedge themselves between layers of myelin and break it down from the inside.
The body does try to repair the damage. Specialized cells called Schwann cells work to rebuild myelin, and this constant cycle of damage and repair is a hallmark of the disease. But over time, if the immune attack isn’t controlled, the underlying nerve fiber itself can sustain permanent injury.
How CIDP Feels Day to Day
The most common symptom is muscle weakness that builds gradually, affecting both sides of the body. Unlike many nerve conditions that start at the fingertips or toes and work inward, CIDP causes weakness in both the upper (thighs, hips) and lower (calves, feet) parts of your limbs. You might first notice difficulty climbing stairs, getting out of a chair, or gripping objects. Reflexes at the knee and ankle typically diminish or disappear early on.
Sensory symptoms often accompany the weakness. These can include tingling, numbness, a “pins and needles” sensation, or an uncomfortable buzzing feeling in the hands and feet. Some people describe a sense of walking on cotton or not being able to feel the ground properly. Balance problems are common because of the combined loss of strength and position sense in the legs.
The defining feature that separates CIDP from its acute cousin, Guillain-Barré syndrome (GBS), is timing. GBS hits fast and peaks within two to three weeks. CIDP is slower, with symptoms worsening over at least eight weeks. Some people experience a steady decline, while others have a relapsing-remitting pattern where symptoms flare, partially improve, then flare again.
Variants That Look Different
Not everyone with CIDP fits the classic pattern. Recognized variants include:
- Distal CIDP (DADS): Symptoms stay concentrated in the hands and feet, following a length-dependent pattern more typical of common neuropathies. It’s often associated with abnormal blood proteins.
- MADSAM (Lewis-Sumner syndrome): Weakness and sensory loss affect individual nerves asymmetrically, so one arm might be affected much more than the other. Over time it can spread to resemble typical CIDP.
- Pure sensory CIDP: Numbness, tingling, and balance problems without significant weakness.
- Pure motor CIDP: Weakness without sensory symptoms, which can look similar to other motor nerve conditions.
- Focal CIDP: Nerve damage limited to one region, such as a single arm or the nerves around the lower spine.
Updated international guidelines from the European Academy of Neurology now classify these as “CIDP variants” rather than “atypical CIDP,” recognizing them as distinct, well-characterized forms of the disease rather than oddities.
How CIDP Is Diagnosed
Diagnosis typically involves three key pieces of evidence. The first is the clinical picture: progressive or relapsing weakness and sensory changes in multiple limbs lasting more than eight weeks, with reduced or absent reflexes.
The second is nerve conduction testing, where small electrical impulses are sent along your nerves to measure how fast and completely signals travel. The hallmark findings are conduction block (where a signal weakens dramatically between two points along the same nerve) and abnormally slow conduction speeds. These patterns distinguish the myelin damage of CIDP from conditions that damage the nerve fiber itself.
The third is a spinal fluid sample. About 90% of people with CIDP have elevated protein levels in their spinal fluid (above 45 mg/dL) without an increase in white blood cells. This combination, high protein with normal cell counts, is a strong supporting clue.
Current diagnostic guidelines use two levels of certainty: CIDP and possible CIDP. Earlier systems had three levels, but research showed the distinction between “definite” and “probable” didn’t meaningfully change diagnostic accuracy, so the categories were simplified.
Treatment and What to Expect
CIDP responds to immune-based treatments, which is one of the things that distinguishes it from many other neuropathies. The three first-line options are intravenous immunoglobulin (IVIg), corticosteroids, and plasma exchange. The choice depends on the specific variant, other health conditions, and practical considerations like how often you can visit an infusion center.
Response to IVIg isn’t always immediate. Only about half of newly treated patients improve after a single course, and many need two or even three courses before a clear benefit appears. For those who do respond, treatment often needs to continue on a regular schedule to maintain the gains.
For long-term maintenance, some people switch from intravenous to subcutaneous immunoglobulin, which you can infuse at home. In one study, 55% of patients who made the switch reported better tolerance compared to their previous IV infusions. The transition uses roughly the same total dose, though some patients do better with slightly higher or lower amounts.
Treatment isn’t necessarily permanent. Between 25% and 40% of patients eventually achieve remission and can stop therapy, though this varies widely and can take months to years. Your neurologist will periodically test whether treatment can be tapered by extending the interval between doses and monitoring for relapse.
Long-Term Outlook
A five-year follow-up study of CIDP patients found that 87% were still able to walk, and 26% achieved complete remission lasting more than two years with normal nerve conduction results. On the other end of the spectrum, 13% had severe disability or remained dependent on ongoing treatment to prevent relapse, and 39% still required some form of immune therapy at the five-year mark.
The biggest factor in long-term outcomes is how much damage accumulates to the nerve fibers underneath the myelin before treatment controls the immune attack. Myelin can regrow, but once the underlying axon is damaged, recovery is limited. This is why early diagnosis matters: the sooner the immune assault is brought under control, the more nerve function is preserved. People with CIDP who respond well to initial treatment and start early generally have the best long-term outlook.